Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: an insight from a phase II clinical study of zinpentraxin alfa

Bibliographic Details
Main Authors: Ryou, H, Sirinukunwattana, K, Wood, R, Aberdeen, A, Rittscher, J, Weinberg, OK, Hasserjian, R, Pozdnyakova, O, Peale, F, Higgins, B, Lundberg, P, Trunzer, K, Harrison, CN, Royston, D
Format: Journal article
Language:English
Published: Wiley 2024
_version_ 1824459057744838656
author Ryou, H
Sirinukunwattana, K
Wood, R
Aberdeen, A
Rittscher, J
Weinberg, OK
Hasserjian, R
Pozdnyakova, O
Peale, F
Higgins, B
Lundberg, P
Trunzer, K
Harrison, CN
Royston, D
author_facet Ryou, H
Sirinukunwattana, K
Wood, R
Aberdeen, A
Rittscher, J
Weinberg, OK
Hasserjian, R
Pozdnyakova, O
Peale, F
Higgins, B
Lundberg, P
Trunzer, K
Harrison, CN
Royston, D
author_sort Ryou, H
collection OXFORD
description
first_indexed 2025-02-19T04:35:44Z
format Journal article
id oxford-uuid:080b1a21-4f79-40f5-aca3-2b682d75d85d
institution University of Oxford
language English
last_indexed 2025-02-19T04:35:44Z
publishDate 2024
publisher Wiley
record_format dspace
spelling oxford-uuid:080b1a21-4f79-40f5-aca3-2b682d75d85d2025-02-04T13:27:38ZQuantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: an insight from a phase II clinical study of zinpentraxin alfaJournal articlehttp://purl.org/coar/resource_type/c_545buuid:080b1a21-4f79-40f5-aca3-2b682d75d85dEnglishSymplectic ElementsWiley2024Ryou, HSirinukunwattana, KWood, RAberdeen, ARittscher, JWeinberg, OKHasserjian, RPozdnyakova, OPeale, FHiggins, BLundberg, PTrunzer, KHarrison, CNRoyston, D
spellingShingle Ryou, H
Sirinukunwattana, K
Wood, R
Aberdeen, A
Rittscher, J
Weinberg, OK
Hasserjian, R
Pozdnyakova, O
Peale, F
Higgins, B
Lundberg, P
Trunzer, K
Harrison, CN
Royston, D
Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: an insight from a phase II clinical study of zinpentraxin alfa
title Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: an insight from a phase II clinical study of zinpentraxin alfa
title_full Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: an insight from a phase II clinical study of zinpentraxin alfa
title_fullStr Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: an insight from a phase II clinical study of zinpentraxin alfa
title_full_unstemmed Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: an insight from a phase II clinical study of zinpentraxin alfa
title_short Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: an insight from a phase II clinical study of zinpentraxin alfa
title_sort quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment an insight from a phase ii clinical study of zinpentraxin alfa
work_keys_str_mv AT ryouh quantitativeanalysisofbonemarrowfibrosishighlightsheterogeneityinmyelofibrosisandaugmentshistologicalassessmentaninsightfromaphaseiiclinicalstudyofzinpentraxinalfa
AT sirinukunwattanak quantitativeanalysisofbonemarrowfibrosishighlightsheterogeneityinmyelofibrosisandaugmentshistologicalassessmentaninsightfromaphaseiiclinicalstudyofzinpentraxinalfa
AT woodr quantitativeanalysisofbonemarrowfibrosishighlightsheterogeneityinmyelofibrosisandaugmentshistologicalassessmentaninsightfromaphaseiiclinicalstudyofzinpentraxinalfa
AT aberdeena quantitativeanalysisofbonemarrowfibrosishighlightsheterogeneityinmyelofibrosisandaugmentshistologicalassessmentaninsightfromaphaseiiclinicalstudyofzinpentraxinalfa
AT rittscherj quantitativeanalysisofbonemarrowfibrosishighlightsheterogeneityinmyelofibrosisandaugmentshistologicalassessmentaninsightfromaphaseiiclinicalstudyofzinpentraxinalfa
AT weinbergok quantitativeanalysisofbonemarrowfibrosishighlightsheterogeneityinmyelofibrosisandaugmentshistologicalassessmentaninsightfromaphaseiiclinicalstudyofzinpentraxinalfa
AT hasserjianr quantitativeanalysisofbonemarrowfibrosishighlightsheterogeneityinmyelofibrosisandaugmentshistologicalassessmentaninsightfromaphaseiiclinicalstudyofzinpentraxinalfa
AT pozdnyakovao quantitativeanalysisofbonemarrowfibrosishighlightsheterogeneityinmyelofibrosisandaugmentshistologicalassessmentaninsightfromaphaseiiclinicalstudyofzinpentraxinalfa
AT pealef quantitativeanalysisofbonemarrowfibrosishighlightsheterogeneityinmyelofibrosisandaugmentshistologicalassessmentaninsightfromaphaseiiclinicalstudyofzinpentraxinalfa
AT higginsb quantitativeanalysisofbonemarrowfibrosishighlightsheterogeneityinmyelofibrosisandaugmentshistologicalassessmentaninsightfromaphaseiiclinicalstudyofzinpentraxinalfa
AT lundbergp quantitativeanalysisofbonemarrowfibrosishighlightsheterogeneityinmyelofibrosisandaugmentshistologicalassessmentaninsightfromaphaseiiclinicalstudyofzinpentraxinalfa
AT trunzerk quantitativeanalysisofbonemarrowfibrosishighlightsheterogeneityinmyelofibrosisandaugmentshistologicalassessmentaninsightfromaphaseiiclinicalstudyofzinpentraxinalfa
AT harrisoncn quantitativeanalysisofbonemarrowfibrosishighlightsheterogeneityinmyelofibrosisandaugmentshistologicalassessmentaninsightfromaphaseiiclinicalstudyofzinpentraxinalfa
AT roystond quantitativeanalysisofbonemarrowfibrosishighlightsheterogeneityinmyelofibrosisandaugmentshistologicalassessmentaninsightfromaphaseiiclinicalstudyofzinpentraxinalfa